Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017


Real-time Estimate Quote. Real-time Estimate Tradegate - 07/29 03:59:25 pm
51.18 EUR   +1.31%
05:26pBAYER AG : Receives a Buy rating from Bernstein
04:39pMaterials Up After GDP Report -- Materials Roundup
10:35aBAYER : to Earmark $4.5 Billion for Potential Roundup Litigation Claims
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer third-quarter adjusted profit gains slightly on strong crop chemicals

10/30/2014 | 03:55am EDT
Logo of German drugmaker Bayer is seen in Leverkusen

FRANKFURT (Reuters) - Germany's largest drugmaker Bayer said underlying core earnings advanced by 1.4 percent, slightly surpassing expectations, on strong sales of pesticides and stroke prevention pill Xarelto.

Bayer said on Thursday its third-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) came in at 2.01 billion euros (1.5 billion pounds), edging past the average estimate of 1.96 billion euros in a Reuters poll.

Adjusted core earnings at the CropScience unit rose by more than a quarter to 278 million euros, shored up by growth in recently launched products, in particular fungicides and herbicides.

Bayer now aims to raise group EBITDA before special items by a mid-single-digit percentage, taking into account the acquisition of Merck & Co. Inc.'s consumer health business it wrapped up on Oct. 1 as well as more favourable currency effects.

It had previously forecast a low to medium single-digit percentage gain.

The euro was up slightly against the U.S. dollar on average over the third quarter but the European currency has lost about 8 percent against the dollar over the last six months, bolstering the euro-value of overseas revenues.

Bayer, the inventor of Aspirin and maker of Yasmin birth-control pills, said pharmaceuticals sales rose by a currency- and portfolio-adjusted 10.3 percent to 3.04 billion euros, boosted by a better-than-expected 70 percent gain of sales in anti-clotting drug Xarelto, mainly used to prevent strokes in the elderly.

"Healthcare performance was okay, but the beat was really driven by CropScience, an area where we had concerns," analysts at brokerage Berenberg said in a note.

The shares gained 3.5 percent at 0830 GMT, outperforming a 1 percent gain in the STOXX Europe 600 Health Care index.

Bayer shares have advanced 7.6 percent over the past three months, outperforming the 2.3 percent gain in the European sector benchmark, as investors welcomed the company's plan to split off and separately list its plastics division.

(Reporting by Ludwig Burger; Editing by Kirsti Knolle and Maria Sheahan)

Valeurs citées dans l'article : Merck & Co., Inc., INCREASE, Bayer AG

ę Reuters 2014
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 1.27% 51.16 Delayed Quote.4.91%
MERCK & CO., INC. -1.79% 76.93 Delayed Quote.-4.24%
All news about BAYER AG
05:26pBAYER AG : Receives a Buy rating from Bernstein
04:39pMaterials Up After GDP Report -- Materials Roundup
10:35aBAYER : to Earmark $4.5 Billion for Potential Roundup Litigation Claims
09:14aBayer posts additional $4.5 billion provision for Roundup litigation
07:54aBayer to Set Aside $4.5 Billion in Provisions for Roundup Case; To Petition U..
07:47aBAYER AG : UBS gives a Buy rating
07/28BAYER : Monsanto told to pay teachers $185M over chemical exposure
07/28BAYER : Considers Appealing Against US Legal Case Over Polychlorinated Biphenyl ..
07/28BAYER : says to appeal U.S. court ruling on PCBs if necessary
07/27Blast in German industrial park kills two, several missing
More news
Sales 2021 41 461 M 49 285 M 49 285 M
Net income 2021 3 600 M 4 280 M 4 280 M
Net Debt 2021 38 636 M 45 927 M 45 927 M
P/E ratio 2021 14,9x
Yield 2021 3,97%
Capitalization 49 632 M 59 002 M 58 998 M
EV / Sales 2021 2,13x
EV / Sales 2022 2,01x
Nbr of Employees 99 329
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 51,16 €
Average target price 64,79 €
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG4.91%58 597
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
NOVARTIS AG0.39%223 750